Title: Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness

Authors: Korryn Bodner<sup>1</sup>, Jesse Knight<sup>1,2</sup>, Mackenzie A. Hamilton<sup>1</sup>, and Sharmistha Mishra<sup>1,2,3,4</sup>

<sup>1</sup> MAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada

<sup>2</sup> Institute of Medical Science, University of Toronto, Toronto, Canada

<sup>3</sup> Division of Epidemiology and Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

<sup>4</sup> Department of Medicine, University of Toronto, Canada

Keywords: vaccine effectiveness; vaccine efficacy; SARS-CoV-2; transmission model; bias

Running Title: Contact influences vaccine effectiveness

### **Corresponding Author:**

Korryn Bodner Rm 326.1, 3rd Floor, St. Michael's Hospital, Unity Health Toronto 209 Victoria Street, 3rd Floor Toronto, Ontario, Canada, M5B 1T8 Phone: +1-416-864-5746 Fax: +1-416-864-5310 Email: <u>k.bodner@mail.utoronto.ca</u>

## Alternate Corresponding Author:

Sharmistha Mishra Rm 315, 3rd Floor, St. Michael's Hospital, Unity Health Toronto 209 Victoria Street, 3rd Floor Toronto, Ontario, Canada, M5B 1T8 Phone: +1-416-864-5746 Fax: +1-416-864-5310 Email: sharmistha.mishra@utoronto.ca

This work was supported by the Canada COVID-19 Immunity Task Force grant (to SM) All authors declare that they have no conflicts of interest.

**Abstract**: Evidence from early observational studies suggested negative vaccine effectiveness for the SARS-CoV-2 Omicron variant. Using transmission modeling, we illustrated how increased contact between vaccinated individuals, vaccinated contact heterogeneity, paired with lower vaccine efficacies could produce negative measurements and how we can identify this mechanism via a key temporal signature.

### Introduction:

Within 4 weeks of the emergence and in the context of rising cases of Omicron, population-based studies in Canada [1], Denmark [2], and the United Kingdom [3] had reported "negative vaccine effectiveness" against SARS-CoV-2. Vaccine effectiveness (V<sub>Eff</sub>) is calculated by comparing the rates of infection between vaccinated and unvaccinated individuals. Thus, a negative V<sub>Eff</sub> measurement suggests that vaccinated individuals were acquiring infections at higher rates than unvaccinated individuals. One potential explanation for the increased infection was that the vaccine increased biological susceptibility, for example, if the virus had evolved to spread faster in vaccinated individuals [4]. However, V<sub>Eff</sub> measurements are calculated using observational data and thus subject to various biases, including but not limited to differences in testing/detection and exposures among vaccinated and unvaccinated populations [5]. Differential exposures by vaccination status could stem from contact heterogeneity.

Contact heterogeneity refers to different levels of contact among and between population subgroups. Increased contact between vaccinated persons, potentially arising due to policies that restrict certain spaces to vaccinated individuals (e.g. vaccine mandates), is one type of contact heterogeneity (hereafter, vaccinated contact heterogeneity). In this study, we test (1) whether vaccinated contact heterogeneity could lead to negative V<sub>Eff</sub> measurements; (2) how this relationship is affected by two components of vaccine efficacy related to transmissibility: vaccine efficacy against susceptibility (VE<sub>s</sub>) and vaccine efficacy against infectiousness (VE<sub>1</sub>) [6]; and if negative measurements can be produced, (3) how this mechanism can be identified.  $VE_S$  and  $VE_I$  reflect the true total vaccine benefit against infection, with  $VE_S$  reflecting the reduced probability of vaccinated recipients acquiring infection and  $VE_I$  reflecting the reduced infectiousness of vaccinated individuals if a breakthrough infection occurs. We hypothesize that both vaccinated contact heterogeneity and the levels of  $VE_S$  and  $VE_I$  contribute to producing negative  $V_{Eff}$ .

## Methods:

Following Shim and Galvani [7], we adapted a simple compartmental SIR (susceptible, infectious, recovered) transmission dynamics model for vaccinated and unvaccinated individuals that assumed an all-or-nothing vaccine type (supplementary Figure 1, [8]). To explicitly account for potential contact differences, the SIR model contained both within-group contact rates for unvaccinated,  $c_{uu}$ , and vaccinated individuals,  $c_{vv}$ , as well as between-group contact rates for unvaccinated with vaccinated,  $c_{uv}$ , and vaccinated with unvaccinated,  $c_{vu}$ .

In all simulations, we assumed 75% vaccination coverage. We explored two different contact scenarios: *homogeneous contact*, where vaccinated and unvaccinated individuals have equal contacts with random ("proportionate") mixing; and *vaccinated heterogeneous contact* where vaccinated individuals have increased within-group contact. In the *homogenous contact* scenario, we assumed 6 daily contacts per-person, reflecting approximate contact rates from U.S. and U.K. during the pandemic [9], and thus defined  $c_{vv} = c_{uv} = 4.5$  and  $c_{uu} = c_{vu} = 1.5$ . In the *vaccinated heterogenous contact* scenario, contacts between vaccinated were increased by 50% compared to the *homogenous contact* scenario ( $c_{vv} = 6.75$ ), with all other parameter values unchanged. We set the recovery rate to be 1/10 [8] and the probability of transmission to be 0.01 such that  $R_0 = 6$  in a fully unvaccinated population with random mixing. Given the uncertainty surrounding vaccine efficacies, two different baseline values of VE<sub>I</sub> and VE<sub>S</sub> were adopted (0.1, 0.5). We also conducted sensitivity analyses, varying VE<sub>I</sub> and VE<sub>S</sub> from 0.1 to 1

and increasing  $c_{vv}$  by 0%- 100% from the *homogenous contact scenario* rates ( $c_{vv}$  = 4.5 - 9). To start our simulations, we introduced one infected vaccinated and unvaccinated individual into our population.

Following Haber [9], we measured  $V_{Eff}(t)$  as 1 – relative risk (t) (RR[t]), defined as:

$$RR(t) = \frac{\frac{CI_{\nu}(t)}{N_{\nu}}}{\frac{CI_{u}(t)}{N_{\mu}}}$$
(1)

where  $CI_{v}(t)$  and  $CI_{u}(t)$  are the cumulative incidences for vaccinated and unvaccinated groups at time t and  $N_{v}$  and  $N_{u}$  are the total numbers of vaccinated and unvaccinated individuals, respectively. We also tracked how differences in the depletion of the proportion of susceptible vaccinated,  $\frac{S_{v}(t)}{N_{v}}$ , and unvaccinated,  $\frac{S_{u}(t)}{N_{u}}$ , interacted explicitly with VE<sub>S</sub> to influence measurements of V<sub>Eff</sub>(t) (supplementary Material 1).

### **Results:**

First, scenarios of homogeneous contact by vaccination status never led to an observed negative V<sub>Eff</sub>. Second, scenarios of heterogeneous contact by vaccination status produced negative V<sub>Eff</sub>, but only in the context of lower vaccine efficacies (VE<sub>S</sub> =0.1, VE<sub>I</sub>=0.1, and VE<sub>S</sub>=0.1, VE<sub>I</sub>=0.5; Figure 1a). Third, negative V<sub>Eff</sub> only occurred during epidemic growth (Figure 1a and b) with V<sub>Eff</sub>(t) becoming positive only when the proportion of susceptible unvaccinated was lower than the combined proportion of susceptible vaccinated was lower than the combined proportion of susceptible vaccinated with the proportion immune due to vaccination (i.e. the level of VE<sub>S</sub>; supplementary Figure

2).

The minimum V<sub>Eff</sub> was moderately influenced by VE<sub>I</sub>, and strongly influenced by the levels of VE<sub>S</sub> and the contact between vaccinated individuals (Figure 1c-d). For example, when VE<sub>S</sub> was less than 0.2 and  $c_{\nu\nu}$  was a 100% higher than the *homogeneous contact* scenario, V<sub>Eff</sub>(t) was strongly negative (< -

0.5). VE<sub>I</sub> was less influential on negative V<sub>Eff</sub> but high levels of VE<sub>I</sub>, (>0.92) could still prevent negative V<sub>Eff</sub> even at very low VE<sub>S</sub> (<0.1) (Figure 1c).

### Discussion:

Our results demonstrated how vaccinated contact heterogeneity, defined as higher contact levels between vaccinated individuals, could lead to observed measurements of negative  $V_{Eff}$ . Thus, we illustrate a plausible scenario where vaccines can be perceived to be non-beneficial - or even harmful – despite providing a benefit to a population (vaccine efficacies > 0).

Vaccinated contact heterogeneity can negatively bias measurements of  $V_{Eff}$ , but observing negative measurements required the underlying vaccine efficacies to be lower– in particular, lower  $VE_S$ . That is, we found that vaccine efficacies can mediate the effect of the contact heterogeneity bias. Given the consistent reports of higher  $V_{Eff}$  against other variants compared to Omicron [e.g. 10], this mediation effect can explain how this bias could be present before Omicron despite the absence of negative measurements.

Beyond testing vaccinated contact heterogeneity feasibility as a mechanism of bias, we also identified a temporal signature in  $V_{Eff}$  measurements that indicates when this mechanism could be the cause of negative  $V_{Eff}$ . In the context of vaccinated contact heterogeneity, negative measurements only occurred during epidemic growth when the proportion of susceptible unvaccinated was higher than the proportion of susceptible vaccinated (mediated by  $VE_S$ ; supplementary Figure 2). In each of the empirical studies, the negative  $V_{Eff}$  measurements coincided with Omicron's epidemic growth stage [1–3]. If measurements of  $V_{Eff}$  are consistently updated and found to change direction later in an epidemic, this would suggest the negative measurement may have been the result of vaccinated contact heterogeneity.

Vaccinated contact heterogeneity is one possible cause of negative  $V_{Eff}$ , but other biases such as selection bias via testing access or health-seeking behaviour [5], as well as higher immunity among unvaccinated from prior infection could also potentially cause negative measurements. Moreover, our analysis focused on an all-or-nothing vaccine type for simplicity, but leaky vaccine type [11] could impart a different temporal pattern for the vaccinated contact heterogeneity bias. Important next steps include exploring other potential biases that may lead to negative  $V_{Eff}$  and including how assumptions surrounding leaky versus all-or-nothing vaccine type may influence  $V_{Eff}$  measures over time.

Although our study was designed to explain potential mechanisms, and not to specify which values of  $VE_S$ ,  $VE_I$  and contact differences most likely cause observed negative measures, the findings have important implications for the conduct and interpretation of observational studies measuring  $V_{Eff}$ . If possible, observational studies must try to address confounding due to vaccinated contact heterogeneity when measuring  $V_{Eff}$  during epidemic growth as this bias could affect measurements for future variants of SARS-CoV-2 and other emerging pathogens. If it is not possible to address confounding, then reports and public communication must ensure that interpretation of  $V_{Eff}$  includes the possibility of this bias to avoid misinterpretation that can amplify vaccine mistrust [12], or wait until the epidemic peak has occurred to update and report measurements of  $V_{Eff}$ .

In this brief report, we highlight one possible pathway for  $V_{Eff}$  to appear negative even when vaccines are beneficial and how this bias could be identified. Our findings not only illustrate a potential mechanism for the negative  $V_{Eff}$  studies of the Omicron variant [1,3], but also provide a potential explanation for observed negative  $V_{Eff}$  in future studies.

Funding: This work was supported by the Canada COVID-19 Immunity Task force grant (to SM).

**Acknowledgements:** We would like to thank Dr. Jeffrey C. Kwong and Sarah A. Buchan for their insight into measuring vaccine effectiveness and KB would like to additionally thank Cedric B. Hunter for their

ongoing support. JK is supported by the Natural Sciences and Engineering Research Council of Canada (NSERC CGS-D) and SM is supported by a Tier 2 Canada Research Chair in Mathematical Modeling and Program Science.

# References

 Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv 2022; :2021.12.30.21268565. Available at: https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v2%0Ahttps://www.medrxiv.o

rg/content/10.1101/2021.12.30.21268565v2.abstract.

- 2. Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv **2021**; :iii–iv.
- UK Health Security Agency. COVID-19 Vaccine Surveillance report: 23 December 2021 (week 51).
  2021. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports. Accessed 4 April 2022.
- Day T, Kennedy DA, Read AF, Gandon S. The evolutionary epidemiology of pathogens during vaccination campaigns. 2021; :1–32.
- 5. Weinberg GA, Szilagyi PG. Vaccine epidemiology: Efficacy, effectiveness, and the translational research roadmap. J Infect Dis **2010**; 201:1607–1610.
- Halloran ME, Longini IM, Struchiner CJ. Design and interpretation of vaccine field studies.
  Epidemiol Rev 1999; 21:73–88.

- 7. Shim E, Galvani AP. Distinguishing vaccine efficacy and effectiveness. Vaccine 2012; 30:6700–6705.
- 8. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol **1984**; 13:87–93.
- Haber, M. Estimation of the direct and indirect effects of vaccination. Stat Med **1999**; 18:2101– 2109.
- 10. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med **2022**; 19.
- 11. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of vaccine direct effects under the test-negative design. Am J Epidemiol **2018**; 187:2686–2697.
- 12. Miller A. Canadian COVID-19 vaccine study seized on by anti-vaxxers highlighting dangers of early research in pandemic. CBC. 2022; Available at: https://www.cbc.ca/news/health/covid-19-vaccine-study-omicron-anti-vaxxers-1.6315890.



**Figure 1.** Vaccine effectiveness and infection dynamics are influenced by contact heterogeneity and vaccine efficacies. Homogeneous contact rates (equal contacts among vaccinated and unvaccinated individuals) and heterogenous contact rates (vaccinated have more contacts with vaccinated individuals) interact with vaccine efficacy against susceptibility (VE<sub>S</sub>) and vaccine efficacy against infectiousness (VE<sub>I</sub>) to influence measurements of vaccine effectiveness over time (a) and the proportion of infected individuals over time (b). Negative vaccine effectiveness becomes positive once the proportion of susceptible unvaccinated individuals became lower than the proportion of susceptible vaccinated individuals combined with the level of VE<sub>S</sub> (grey vertical lines; supplementary Material 1). The minimum vaccine effectiveness was sensitive to VE<sub>I</sub> (c), the % increase in contact between vaccinated individuals (d), and VE<sub>S</sub> (c and d). Note that colours in (c) and (d) indicate the minimum negative vaccine effectiveness observed for a given simulation with >0 indicating a non-negative measurement.